Nature Communications (Feb 2022)
Nationally representative SARS-CoV-2 antibody prevalence estimates after the first epidemic wave in Mexico
Abstract
SARS-CoV-2 seroprevalence surveys provide estimates of the extent of prior infection in a population. In this nationally representative survey from Mexico, the authors estimate seroprevalence after the first epidemic wave at ~25%, with variation by region, age, socioeconomic status, and education level.